Dicerna Pharma (DRNA) Receives FDA Orphan Drug Designation for PH1 Therapeutic Candidate
Tweet Send to a Friend
Dicerna Pharma (NASDAQ: DRNA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
